利用合成致命弱点进行癌症治疗
Exploiting synthetic lethal vulnerabilities for cancer therapy
摘要:
合成致死性是指两个或多个遗传事件(通常影响不同的基因)的组合,其中事件的共同发生导致细胞或生物体致死,但当仅发生其中一个事件时,细胞或生物体仍保持活力。在过去的几年里,合成致死性因其在选择性杀死癌细胞方面的价值而受到关注:通过靶向癌症中改变基因的合成致死伴侣,只有癌细胞可以被杀死,而正常细胞不会被杀死。在最近的一项研究中,我们发现癌症中遗传事件的相互排斥组合暗示了自然发生的合成致死组合,因此通过系统地挖掘这些组合,我们可以确定癌症的新治疗靶点。在此基础上,我们确定了718个基因的列表,这些基因与癌症中的6个DNA损伤反应基因相互排斥。在这里,我们扩展这些结果,以确定一个子集的43个基因,其过度表达与显着较差的生存率在雌激素受体阴性乳腺癌,从而提供了一个有前途的名单潜在的治疗靶点和/或生物标志物。
英文摘要:
Synthetic lethality refers to a combination of two or more genetic events (typically affecting different genes) in which the co-occurrence of the events results in cell or organismal lethality, but the cell or organism remains viable when only one of the events occurs. Synthetic lethality has gained attention in the last few years for its value in selective killing of cancer cells: by targeting the synthetic lethal partner of an altered gene in cancer, only the cancer cells can be killed while sparing normal cells. In a recent study, we showed that mutual exclusive combinations of genetic events in cancer hint at naturally occurring synthetic lethal combinations, and therefore by systematically mining for these combinations we can identify novel therapeutic targets for cancer. Based on this, we had identified a list of 718 genes that are mutually exclusive to six DNA-damage response genes in cancer. Here, we extend these results to identify a subset of 43 genes whose over-expression correlates with significantly poor survival in estrogen receptor-negative breast cancers, and thus provide a promising list of potential therapeutic targets and/or biomarkers.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。